Skip to main content

Clinical trial MIDAS

MInimal residual Disease Adapted Strategy: frontline therapy for patients eligible for autologous stem cell transplantation less than 66 years; a prospective study from the French cooperative group (IFM) (MIDAS ; IFM2020-02)

Organ Myeloma
Trial status Trial closed for recruitment
Trial type
Interventional with experimental drug
Phase Trial phase 3
Academic trial Oui
Sponsor IFM
EudraCT Identifier 2020-005216-21
Inclusion criteria Newly diagnosed subjects eligible for high dose therapy and autologous stem cell transplantation
Last update